These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit. Sreetama SC; Chandra G; Van der Meulen JH; Ahmad MM; Suzuki P; Bhuvanendran S; Nagaraju K; Hoffman EP; Jaiswal JK Mol Ther; 2018 Sep; 26(9):2231-2242. PubMed ID: 30166241 [TBL] [Abstract][Full Text] [Related]
5. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. Lennon NJ; Kho A; Bacskai BJ; Perlmutter SL; Hyman BT; Brown RH J Biol Chem; 2003 Dec; 278(50):50466-73. PubMed ID: 14506282 [TBL] [Abstract][Full Text] [Related]
6. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. Cagliani R; Magri F; Toscano A; Merlini L; Fortunato F; Lamperti C; Rodolico C; Prelle A; Sironi M; Aguennouz M; Ciscato P; Uncini A; Moggio M; Bresolin N; Comi GP Hum Mutat; 2005 Sep; 26(3):283. PubMed ID: 16100712 [TBL] [Abstract][Full Text] [Related]
7. Myofiber damage precedes macrophage infiltration after in vivo injury in dysferlin-deficient A/J mouse skeletal muscle. Roche JA; Tulapurkar ME; Mueller AL; van Rooijen N; Hasday JD; Lovering RM; Bloch RJ Am J Pathol; 2015 Jun; 185(6):1686-98. PubMed ID: 25920768 [TBL] [Abstract][Full Text] [Related]
8. Dysferlin, annexin A1, and mitsugumin 53 are upregulated in muscular dystrophy and localize to longitudinal tubules of the T-system with stretch. Waddell LB; Lemckert FA; Zheng XF; Tran J; Evesson FJ; Hawkes JM; Lek A; Street NE; Lin P; Clarke NF; Landstrom AP; Ackerman MJ; Weisleder N; Ma J; North KN; Cooper ST J Neuropathol Exp Neurol; 2011 Apr; 70(4):302-13. PubMed ID: 21412170 [TBL] [Abstract][Full Text] [Related]
9. Myofibers deficient in connexins 43 and 45 expression protect mice from skeletal muscle and systemic dysfunction promoted by a dysferlin mutation. Fernández G; Arias-Bravo G; Bevilacqua JA; Castillo-Ruiz M; Caviedes P; Sáez JC; Cea LA Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165800. PubMed ID: 32305450 [TBL] [Abstract][Full Text] [Related]
10. Treatment with galectin-1 improves myogenic potential and membrane repair in dysferlin-deficient models. Vallecillo-Zúniga ML; Rathgeber MF; Poulson PD; Hayes S; Luddington JS; Gill HN; Teynor M; Kartchner BC; Valdoz J; Stowell C; Markham AR; Arthur C; Stowell S; Van Ry PM PLoS One; 2020; 15(9):e0238441. PubMed ID: 32881965 [TBL] [Abstract][Full Text] [Related]
12. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B. Gushchina LV; Bhattacharya S; McElhanon KE; Choi JH; Manring H; Beck EX; Alloush J; Weisleder N Mol Ther; 2017 Oct; 25(10):2360-2371. PubMed ID: 28750735 [TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between outcomes of membrane repair assay and correction of dystrophic changes in experimental therapeutic strategy in dysferlinopathy. Lostal W; Bartoli M; Roudaut C; Bourg N; Krahn M; Pryadkina M; Borel P; Suel L; Roche JA; Stockholm D; Bloch RJ; Levy N; Bashir R; Richard I PLoS One; 2012; 7(5):e38036. PubMed ID: 22666441 [TBL] [Abstract][Full Text] [Related]
14. Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle. Klinge L; Harris J; Sewry C; Charlton R; Anderson L; Laval S; Chiu YH; Hornsey M; Straub V; Barresi R; Lochmüller H; Bushby K Muscle Nerve; 2010 Feb; 41(2):166-73. PubMed ID: 20082313 [TBL] [Abstract][Full Text] [Related]
15. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Ho M; Post CM; Donahue LR; Lidov HG; Bronson RT; Goolsby H; Watkins SC; Cox GA; Brown RH Hum Mol Genet; 2004 Sep; 13(18):1999-2010. PubMed ID: 15254015 [TBL] [Abstract][Full Text] [Related]